6CM
ARCT icon

683 Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

683 Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-24,000
Closed -$147K – 240
2025
Q4 		$147K Buy
+24,000
New +$259K 0.01% 222

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

683 Capital Management's ARCT Position: Q4 2020 in Review

683 Capital Management sold out of Arcturus Therapeutics (ARCT) in Q4 2020, closing a stake of 16,855 shares — an estimated $723K sold.

683 Capital Management first reported a position in ARCT in Q4 2019 and held it in 4 quarters. The position peaked at $788K in Q2 2020. 135 funds tracked by Wall St. Rank hold ARCT as of Q4 2020.

  • 683 Capital Management reported no remaining Arcturus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • 683 Capital Management sold 16,855 Arcturus Therapeutics shares in Q4 2020, an estimated $723K.
  • 683 Capital Management first reported a position in Arcturus Therapeutics in Q4 2019 and held it in 4 quarters.
  • 683 Capital Management's Arcturus Therapeutics position peaked at $788K in Q2 2020.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2020.

Based on 683 Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.